Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited
- 1 March 2009
- journal article
- editorial
- Published by Elsevier in Cancer Cell
- Vol. 15 (3) , 167-170
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor AngiogenesisCancer Cell, 2009
- VEGF inhibition: insights from preclinical and clinical studiesCell and tissue research, 2008
- Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 2008
- Challenges and Pitfalls of Combining Targeted Agents in Phase I StudiesJournal of Clinical Oncology, 2008
- Hypoxia and cancerJournal of Molecular Medicine, 2007
- Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacyProceedings of the National Academy of Sciences, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007
- Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialThe Lancet, 2006
- Phase II Study of Sorafenib in Patients With Advanced Hepatocellular CarcinomaJournal of Clinical Oncology, 2006